tavatecan
Start here
Takeda and Innovent Biologics announced results from the international Phase 3 G-HOPE-001 study of the CLDN18.2-targeted ADC arcotatug tavatecan. The study met both primary endpoints of progression-free survival (PFS) and overall survival (OS) in previously multiply treated patients with CLDN18.2-positive advanced gastric cancer, significantly extending survival.
Excerpted from mp.weixin.qq.com
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comTakeda and Innovent CLDN18.2 ADC arcotatug tavatecan Phase 3 G-HOPE-001 Meets Dual PFS and OS Primary Endpoints
Takeda and Innovent Biologics announced results from the international Phase 3 G-HOPE-001 study of the CLDN18.2-targeted ADC arcotatug tavatecan. The study met both primary endpoints of progression-free survival (PFS) and overall survival (OS) in previously multiply treated patients with CLDN18.2-positive advanced gastric cancer, significantly extending survival.
Heat trend for this story
Heat now 27·Peak in the comparable set 49 (Oct 24 15:00)·Change over 24h in the comparable set -37%·Participants now 7
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.